Combination of Palonosetron, Aprepitant, and Dexamethasone As Primary Antiemetic Prophylaxis for Cisplatin-based Chemotherapy

Overview

Journal Biomed J

Publisher Elsevier

Specialty General Medicine

Date 2016 Apr 24

PMID 27105599

Citations 4

Authors

Chan-Keng Yang

Chiao-En Wu

Chuang-Chi Liaw

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to evaluate the efficacy of combined treatment with the long-acting 5-hydroxytryptamine receptor-3 antagonist, palonosetron, the neurokinin-1 receptor antagonist, oral aprepitant, and dexamethasone as primary antiemetic prophylaxis for cancer patients receiving highly emetogenic cisplatin-based chemotherapy.

Methods: Chemotherapy-naïve patients received the triple combination of palonosetron (0.25 mg), aprepitant (125 mg on day 1 and 80 mg on days 2 and 3), and dexamethasone (20 mg) from the beginning of highly emetogenic chemotherapy with cisplatin-based (≥50 mg/m(2)) regimens. The primary endpoint was a complete response (no emetic episodes and no rescue antiemetics) during the days 1-6.

Results: Sixty-nine hospitalized patients receiving chemotherapy from September 2012 to October 2014 were analyzed. Complete response of vomiting and nausea-free was achieved in 97.1% and 85.5% of patients in the first cycle, respectively, and 96.7% and 83.6% of patients in the second cycle, respectively. Common adverse events in all 69 patients included constipation (43%), hiccup (26%), and headache (4%).

Conclusion: The combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cancer patients with highly emetogenic cisplatin-based chemotherapy is effective.

Citing Articles

Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients.

Suzuki Y, Naito T, Shibata K, Hosokawa S, Kawakami J Cancer Chemother Pharmacol. 2023; 91(6):481-490.

PMID: 37140601 DOI: 10.1007/s00280-023-04537-4.

Perspectives on the Medical, Quality of Life, and Economic Consequences of Hiccups.

Hendrix K, Wilson D, Kievman M, Jatoi A Curr Oncol Rep. 2019; 21(12):113.

PMID: 31858286 DOI: 10.1007/s11912-019-0857-4.

Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy.

Lv X, Zhao M, Wang Y, Hu X, Wu J, Jiang X Drug Des Devel Ther. 2016; 10:3933-3946.

PMID: 27942204 PMC: 5138022. DOI: 10.2147/DDDT.S116286.

Helicobacter pylori's road to colonization.

Louise Walton E Biomed J. 2016; 39(1):1-4.

PMID: 27105593 PMC: 6140135. DOI: 10.1016/j.bj.2016.03.001.

References

Gralla R, Lichinitser M, van der Vegt S, Sleeboom H, Mezger J, Peschel C . Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14(10):1570-7. DOI: 10.1093/annonc/mdg417. View

Stoltz R, Cyong J, Shah A, Parisi S . Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004; 44(5):520-31. DOI: 10.1177/0091270004264641. View

Grunberg S . Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2006; 18(2):233-40. DOI: 10.1093/annonc/mdl347. View

Forni C, Ferrari S, Loro L, Mazzei T, Beghelli C, Biolchini A . Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer. 2000; 8(2):131-3. DOI: 10.1007/s005200050027. View

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

Liaw C, Chang H, Liau C, Huang J, Lin Y, Chen J . Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003; 26(1):12-5. DOI: 10.1097/00000421-200302000-00003. View

Herrington J, Jaskiewicz A, Song J . Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008; 112(9):2080-7. DOI: 10.1002/cncr.23364. View

Lindley C, McCune J, Thomason T, Lauder D, Sauls A, Adkins S . Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract. 1999; 7(2):59-65. DOI: 10.1046/j.1523-5394.1999.07205.x. View

Basch E, Prestrud A, Hesketh P, Kris M, Feyer P, Somerfield M . Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29(31):4189-98. PMC: 4876353. DOI: 10.1200/JCO.2010.34.4614. View

10.

Liaw C, Wang C, Chang H, Wang H, Huang J, Lin Y . Cisplatin-related hiccups: male predominance, induction by dexamethasone, and protection against nausea and vomiting. J Pain Symptom Manage. 2005; 30(4):359-66. DOI: 10.1016/j.jpainsymman.2005.08.008. View

11.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A . Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98(11):2473-82. DOI: 10.1002/cncr.11817. View

12.

Grunberg S, Deuson R, Mavros P, Geling O, Hansen M, Cruciani G . Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004; 100(10):2261-8. DOI: 10.1002/cncr.20230. View

13.

Takeshima N, Matoda M, Abe M, Hirashima Y, Kai K, Nasu K . Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. Support Care Cancer. 2014; 22(11):2891-8. DOI: 10.1007/s00520-014-2280-6. View

14.

Aapro M, Grunberg S, Manikhas G, Olivares G, Suarez T, Tjulandin S . A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006; 17(9):1441-9. DOI: 10.1093/annonc/mdl137. View

15.

Schmoll H, Aapro M, Poli-Bigelli S, Kim H, Park K, Jordan K . Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006; 17(6):1000-6. DOI: 10.1093/annonc/mdl019. View

16.

Roila F, Herrstedt J, Aapro M, Gralla R, Einhorn L, Ballatori E . Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21 Suppl 5:v232-43. DOI: 10.1093/annonc/mdq194. View

17.

Hickok J, Roscoe J, Morrow G, Bole C, Zhao H, Hoelzer K . 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005; 6(10):765-72. PMC: 1646426. DOI: 10.1016/S1470-2045(05)70325-9. View

18.

Hesketh P . Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999; 4(3):191-6. View

19.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H . Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115-24. DOI: 10.1016/S1470-2045(08)70313-9. View

20.

Basch E . The missing voice of patients in drug-safety reporting. N Engl J Med. 2010; 362(10):865-9. PMC: 3031980. DOI: 10.1056/NEJMp0911494. View